複雑性尿路感染症に対するFortimicinとCefotax併用療法の臨床的評価

Abstract

63例の複雑性尿路感染症患者に対してFortimicin(R) 400 mg/日, Cefotax(R) 2 g/日の5日間の併用療法を行い, 臨床的効果を評価した.1)単独感染例は52例であり, このうち30例はカテーテル留置症例であった.混合感染例は11例であり, うち10例はカテーテル留置例であった.2) Fortimicin(R)とCefotax(R)の併用療法の総合有効率は単独感染例で67.3%で, 混合感染例で72.7%であり, 全症例の有効率は68.3%であった.3)分離された尿中細菌株76株のうちおもな細菌はE. coli 15株, Ps. aeruginosa 13株, S. marcescens 12株であり, それぞれの菌消失率は100%, 38.5%, 83.3%であった.4) Fortimicin(R)とCefotax(R)の併用療法による重篤な副作用や血液検査所見の異常はみられなかった

Clinical efficacy of combination therapy using Fortimicin (ASTM) and Cefotax (CTX) was studied in 63 patients with complicated urinary tract infections. The patients received 200 mg of ASTM i.m. and 1 g of CTX i.v. twice a day. The overall clinical efficacy of the treatment was evaluated by criteria proposed by the Japanese UTI Committee. The overall clinical efficacy rate was 68.3%. The rate was 67.3% in the patients with single bacterial infection and 72.7% in those with mixed infections. Subjective side effects were observed in one of the patients. Drug related aggravation in laboratory tests was observed in 8 items in 8 patients, but these were mild changes. We concluded that combination therapy with ASTM and CTX was useful for the treatment of complicated urinary tract infections.